No Data
No Data
Cocrystal Pharma Boosts Executive and Director Compensation
Cocrystal Pharma Advances CDI-988 Into Phase 1 MAD Cohorts
Express News | Cocrystal Pharma Inc: Topline Study Results Are Expected in Late 2024 or Early 2025
Express News | Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor Cdi-988 Into Phase 1 Multiple-Ascending Dose Cohorts
Toll Brothers To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Cocrystal Pharma Is Maintained at Buy by HC Wainwright & Co.
No Data
No Data